Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects
NCT06884514Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- Apr 2025
- Primary completion
- May 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin and midomafetamine (4 arms), sponsored by University Hospital Basel. Primary endpoints: Acute Subjective effects I at 18 months, Acute Subjective effects II at 18 months and 5 more. Started Apr 2025; status: completed.
02
Drugs
psilocybinmidomafetamine
Beyond the preview
Go deeper on NCT06884514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06884514.